透明细胞肾细胞癌的转移风险:一个纳入性别、肿瘤大小和分级的工具
基于丹麦全国DaRenCa Study-3中2010—2018年确诊的2109例初诊非转移性透明细胞肾细胞癌(ccRCC)与450例转移性ccRCC病例,采用逻辑回归分析诊断变量与转移的关联,并按肿瘤大小估算转移比例。多变量分析显示性别、肿瘤大小和分级与转移性ccRCC相关,而年龄不相关;转移比例随肿瘤增大和分级升高而增加。作者认为该风险表有助于对接受预期管理的ccRCC患者讨论进展为转移的风险。
要点
- 性别、肿瘤大小和分级与转移性ccRCC相关,年龄不相关。
- 女性40 mm肿瘤的转移比例:1级2.9%(95%CI 1.7-4.8%),4级16%(95%CI 12-22%)。
- 女性70 mm肿瘤的转移比例:1级6.6%(95%CI 4.0-11%),4级31%(95%CI 25-38%)。
核心结论
- 性别、肿瘤大小和分级与转移性ccRCC相关,年龄不相关,作者认为所呈现的风险表是讨论ccRCC预期管理患者转移风险的有价值工具。
研究设计与样本
- 在丹麦全国Danish Multidisciplinary Renal Cancer Group(DaRenCa)Study-3中识别2010—2018年经组织病理学确诊的ccRCC患者;采用逻辑回归分析诊断变量与转移的关联,并基于逻辑回归模型按肿瘤大小评估转移比例;研究纳入2109例初诊非转移性ccRCC病例和450例转移性ccRCC病例。
主要发现
- 多变量逻辑回归分析发现性别、肿瘤大小和分级与转移性ccRCC相关,而年龄不相关。
- 转移病例比例随肿瘤尺寸增大和分级升高而增加。
- 女性40 mm肿瘤的转移比例为1级2.9%(95%CI 1.7-4.8%)、4级16%(95%CI 12-22%);女性70 mm肿瘤的转移比例为1级6.6%(95%CI 4.0-11%)、4级31%(95%CI 25-38%)。
- 肿瘤<40 mm且分级1-2级时,肿瘤尺寸每增加10 mm转移病例比例的绝对增幅<2%。
- 肿瘤尺寸>50 mm和/或分级3-4级时,肿瘤每增加10 mm转移病例比例的绝对增幅为中等(2-<4%)至高(≥4%)。
临床怎么用
- 作者认为所呈现的风险表为讨论接受预期管理的ccRCC患者进展为转移的风险提供了有价值的工具,使临床医生能够做出更明智的、基于证据的决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify predictors of metastases, estimate the proportion of metastatic clear cell renal cell carcinoma (ccRCC) cases according to these predictors, and subsequently create a risk table showing the absolute difference in metastasis proportion for each 10 mm increase in tumour size. PATIENTS AND METHODS: Patients diagnosed with histopathological confirmed ccRCC in 2010-2018 in Denmark identified in the nationwide Danish Multidisciplinary Renal Cancer Group (DaRenCa) Study-3. Association between diagnostic variables and metastases were assessed with logistic regression analyses. Proportion of cases with metastases were assess based on tumour sizes using a logistic regression model. RESULTS: The study included 2109 cases with non-metastatic ccRCC at diagnosis and 450 cases with metastatic ccRCC. Multivariable logistic regression analyses found sex, tumour size and grade were associated with metastatic ccRCC, whereas age was not. The proportion of cases with metastasis increased with larger tumours sizes and higher grade. As an example, the proportion of metastases in female cases with tumour size of 40 mm was 2.9% (95% confidence interval [CI] 1.7-4.8%) in Grade 1 and 16% (95% CI 12-22%) in cases with Grade 4. Comparable numbers in cases with a tumour size of 70 mm were 6.6% (95% CI 4.0-11%) and 31% (95% CI 25-38). The absolute increase in the proportion of cases with metastases with a 10 mm increase in size was <2% for tumours <40 mm and Grade 1-2. In contrast, cases with tumour sizes >50 mm and/or Grade 3-4 had a moderate (2-<4%) to high (≥4%) absolute increase in the proportion of cases with metastases with each 10 mm increase. CONCLUSION: The risk table presented offers a valuable tool for discussing the risk of progression to metastases in patients under expected management for ccRCC, enabling clinicians to make more informed, evidence-based decisions.
引用
- Thomsen FF, Westerberg M, Petersson RD, et al. Metastatic risk in clear cell renal cell carcinoma: a tool incorporating sex, size, and grade. BJU Int. 2024. PMID: 39703075. doi:10.1111/bju.16624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。